Active Ingredient(s): Hyaluronidase
FDA Approved: * October 26, 2004
Pharm Company: * AMPHASTAR PHARM
Category: Medical Device

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Amphadase Overview

The hyaluronidases (EC are a family of enzymes that degrade hyaluronic acid. Karl Meyer [1] classified these enzymes in 1971 into three distinct groups, a scheme based on the enzyme reaction products. The three main types of hyaluronidases are two classes of eukaryotic endoglycosidase hydrolases and a prokaryotic lyase-type of glycosidase. In humans, there are six associated genes, including HYAL1, HYAL2, HYAL3, and PH-20/SPAM1.[2] Contents 1 Use as a drug 2 Role in cancer 3 ...

Read more Amphadase Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Amphadase Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 1,500 units/vial, 150 units/ml, 150 units/vial, 150unit/ml, 150USPunits/ml, 200 units/vial, 200units/ml, 6,200 units/vial
  • Powder for Reconstitution: 6200IU/5ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Amphadase: (1 result)

Sorted by National Drug Code
  • 0548-9090 Amphadase 150 [usp'u]/Ml Subcutaneous Injection by Amphastar Pharmaceuticals, Inc.

Other drugs which contain Hyaluronidase or a similar ingredient: (5 results)